Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Cited by (1,000)

Items 601–700 of 1,000

1. Maintenance therapy in multiple myeloma
   Prerna Mewawalla, Abhishek R. Chilkulwar · 2016 · Therapeutic Advances in Hematology
2. Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome
   Francesco Autore, Idanna Innocenti, Marco Luigetti, Nicola Piccirillo, Federica Sorà, Patrizia Chiusolo, Simona Sica, Andrea Paolo Bacigalupo, Luca Laurenti · 2017 · Hematological Oncology
3. Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells
   Antonio Olry de Labry Lima, Vicente Gimeno‐Ballester, Rafael Ríos Tamayo, David Mark Epstein, Antonio Matas Hoces, Esmeralda Ríos Sánchez, Leticia García‐Mochón, Emilio Jesús Alegre Del Rey · 2019 · Bone Marrow Transplantation
4. Lenalidomide
   Katja Christina Weisel, Lothar Kanz · 2014 · Recent results in cancer research/Recent Results in Cancer Research
5. Hematopoietic Stem Cell Transplantation
   Qaiser Bashir, Richard E. Champlin · 2014 · Elsevier eBooks
6. Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
   Naoka Murakami, Christopher D. Blosser, Allison B. Webber, Gaurav Gupta, Neeraj Singh, Samhita Boppana, Samip R. Master, Raviprasenna K. Parasuraman, Erica Leigh Campagnaro, Anuja Java et al. · 2025 · Kidney International
7. Autologous Hematopoietic Stem Cell Transplantation for Patients With Multiple Myeloma
   Teresa S. Miceli, Kathryn E. Lilleby, Kimberly Ann Noonan, Sandra E Kurtin, Beth M Faiman, Patricia A Mangan · 2013 · Clinical journal of oncology nursing
8. First linevsdelayed transplantation in myeloma: Certainties and controversies
   Annamaria Brioli · 2016 · World Journal of Transplantation
9. Young Adults with Multiple Myeloma
   Hollie Devine, Daniel Verina · 2017 · Seminars in Oncology Nursing
10. Lenalidomide Maintenance Post-Transplantation in Newly Diagnosed Multiple Myeloma: Real-World Outcomes and Costs
    Parameswaran Hari, Brian L. Ung, Safiya Abouzaid, Amit Agarwal, Kejal Parikh · 2019 · Future Oncology
11. Therapy-related B-lymphoblastic leukemia after multiple myeloma
    Michael Edward Kallen, Rima Koka, Zeba N. Singh, Yi Ning, Mehmet Hakan Kocoglu, Ashraf Z. Badros, Sandrine Niyongere, Vu H. Duong, Ashkan Emadi, Maria R. Baer · 2022 · Leukemia Research Reports
12. An update on the use of lenalidomide for the treatment of multiple myeloma
    Flora Zagouri, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2015 · Expert Opinion on Pharmacotherapy
13. Challenges in multiple myeloma diagnosis and treatment
    Saulius Kazmiems Girnius, Nikhil C. Munshi · 2013 · Leukemia Supplements
14. When to recommend allogeneic transplant in multiple myeloma
    Morie Abraham Gertz · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
15. Have drug combinations supplanted stem cell transplantation in myeloma?
    Antonio Pierangelo Palumbo, Federica Cavallo · 2012 · PubMed
16. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
    Panagiotis Samaras, Mario J. Bargetzi, Daniel C. Betticher, Michel André Duchosal, Dominik A. Heim, Urs Hess, Nicolas Ketterer, Erika Lerch, Thomas Matthes, Ulrich Mey et al. · 2015 · Swiss Medical Weekly
17. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan
    Tsuyoshi Muta, Toshihiro Miyamoto, Tomohiko Kamimura, Yoshinobu Kanda, Masaharu Nohgawa, Yasunori Ueda, Koji Iwato, Osamu Sasaki, Takehiko Mori, Naoyuki Uchida et al. · 2018 · Acta Haematologica
18. Assessing the impact of a matching‐adjusted indirect comparison in a Bayesian network meta‐analysis
    Joy Leahy, Cathal Walsh · 2019 · Research Synthesis Methods
19. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
    Benjamin T. Diamond, Kylee H. Maclachlan, David J. Chung, Alexander M. Lesokhin, Ola Landgren · 2020 · Best Practice & Research Clinical Haematology
20. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation
    Aimaz Afrough, Oren Pasvolsky, Junsheng Ma, Samer Ali Srour, Qaiser Bashir, Neeraj Y. Saini, Chitra M. Hosing, Uday Popat, Partow Kebriaei, Ruby Delgado et al. · 2022 · Transplantation and Cellular Therapy
21. Steps towards a Multiple Myeloma Cure?
    Alessandro Gozzetti, Monica Bocchia · 2022 · Journal of Personalized Medicine
22. Newly diagnosed multiple myeloma: making sense of the menu
    Caitlin L. Costello · 2022 · Hematology
23. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
    Minjie Gao, Lu Gao, Guang Yang, Tao Yi, Van S. Tompkins, Xiaosong Wu, Hongwei Xu, Fenghuang Zhan, Jumei Shi · 2014 · PubMed Central
24. Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
    Rachid Baz, Kenneth H. Shain, Mohamad A. Hussein, Ji‐Hyun Lee, Daniel M. Sullivan, Elizabeth Finley Oliver, Lisa Ann Nardelli, Lisa Nodzon, Xiuhua Zhao, Jose Leonel Ochoa-Bayona et al. · 2013 · American Journal of Hematology
25. Frontline Therapy for Multiple Myeloma: A Concise Review of the Evidence Based on Randomized Clinical Trials
    Sobia Yaqub, Gabriela Ballester, Oscar Ballester · 2013 · Cancer Investigation
26. Should minimal residual disease negativity be the end point of myeloma therapy?
    Kenneth Carl Anderson · 2017 · Blood Advances
27. Plasma cell diseases and organ transplant: A comprehensive review
    Andrew J. Cowan, Christopher K. Johnson, Edward N. Libby · 2018 · American Journal of Transplantation
28. The molecular biology of multiple myeloma
    Wee Joo Chng, Peter Leif Bergsagel · 2019 · Wiley eBooks
29. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
    Tommasina Guglielmelli, Antonio Pierangelo Palumbo · 2015 · Expert Review of Hematology
30. Myeloma Is Not a Single Disease
    Sagar Lonial, Ajay K. Nooka · 2016 · Journal of Oncology Practice
31. Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic Strategies
    Henry Sutanto, Pradana Zaky Romadhon, Vembi Rizky Fatmawati, Alief Waitupu, Bagus Aditya Ansharullah, Betty Rachma, Elisa Elisa, Laras Pratiwi, Galih Januar Adytia · 2025 · Hemato
32. New Developments in Post-transplant Maintenance Treatment of Multiple Myeloma
    Hong Liu, Philip L. McCarthy · 2013 · Seminars in Oncology
33. Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy
    Jordan Mark Schecter, Suzanne Lentzsch · 2013 · Current Hematologic Malignancy Reports
34. Role of Consolidation/Maintenance Therapy in Multiple Myeloma
    Antonio Pierangelo Palumbo, Roberto Mina, Chiara Cerrato, Federica Cavallo · 2013 · Clinical Lymphoma Myeloma & Leukemia
35. Sequencing of nontransplant treatments in multiple myeloma patients with active disease
    Andrew Jenho Yee, Noopur S Raje · 2016 · Hematology
36. Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies
    Khalid Ahmed Al‐Anazi · 2019 · IntechOpen eBooks
37. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma
    Laurent Garderet, Frédérique Kuhnowski, Benoit Berge, Murielle Roussel, Laure Devlamynck, Marie Odile Petillon, Martine Escoffre‐Barbe, Ingrid Lafon, Thierry T.F. Facon, Xavier P Leleu et al. · 2023 · British Journal of Haematology
38. Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
    Zhe Zhuang, Ying Tian, Lei Shi, Dongmei Zou, Ru Feng, Wei-Wei Tian, Hong‐Jeng Yu, Fei Dong, Aijun Liao, Yanping Ma et al. · 2023 · Frontiers in Oncology
39. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma
    Yosuke Okada, Fumihiko Kimura, Naoki Kurita, Hiroyuki Takahashi, Yutaka Shimazu, Shohei Mizuno, Naoyuki Uchida, Keisuke Kataoka, Nobuhiro Hiramoto, Shuichi Ota et al. · 2023 · Cytotherapy
40. Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
    Antonio Giovanni Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich · 2023 · Biomedicines
41. Induction Therapy for Newly Diagnosed Multiple Myeloma
    Sagar Lonial, Jesús F. San Miguel · 2013 · Journal of the National Comprehensive Cancer Network
42. Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Heinz Ludwig, Peter Sonneveld · 2012 · Leukemia Research
43. Thrombosis in Myeloma treated with IMiDs
    Xavier P Leleu · 2012 · Thrombosis Research
44. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Philippe Moreau, Sergio Giralt · 2012 · Leukemia Research
45. Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?
    Sergio Giralt, Guenther Koehne · 2013 · Current Hematologic Malignancy Reports
46. Re-Examining the Role of High-Dose Chemotherapy in the Treatment of Light Chain Amyloidosis
    Steven Michael Devine · 2013 · Transplantation and Cellular Therapy
47. Oral ixazomib maintenance therapy in multiple myeloma
    Massimo Offidani, Laura Corvatta, Silvia Gentili, Laura Maracci, Pietro Leoni · 2015 · Expert Review of Anticancer Therapy
48. The safety of pomalidomide for the treatment of multiple myeloma
    John R Jones, Charlotte Pawlyn, Faith E. Davies, Gareth John Morgan · 2016 · Expert Opinion on Drug Safety
49. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
    Ho Sup Lee, Chang‐Ki Min · 2016 · The Korean Journal of Internal Medicine
50. Lenalidomide‐induced eosinophilic pneumonia
    Andrew Toma, Aaron P. Rapoport, ALLEN P. BURKE, Ashutosh Sachdeva · 2017 · Respirology Case Reports
51. Post‐transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review
    Fatimah Al‐Ani, Martha Louzada · 2017 · European Journal Of Haematology
52. Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
    Satoshi Kimura, Hiroshi Ohkawara, Kazuei Ogawa, Mizuko Tanaka, Takahiro Sano, Kayo Harada‐Shirado, Hiroshi Takahashi, Koki Ueda, Akiko Shichishima-Nakamura, Hayato Matsumoto et al. · 2018 · Internal Medicine
53. Risk adapted post-transplant maintenance in multiple myeloma
    Iuliana Vaxman, Morie Abraham Gertz · 2019 · Expert Review of Hematology
54. Role of autologous bone marrow transplant in multiple myeloma
    Margarita Blanes, Javier de la Rubia · 2012 · Current Opinion in Oncology
55. Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study
    Anna Kalff, Nola Kennedy, Angela Smiley, Henry Miles Prince, Andrew Warwick Roberts, Kenneth Francis Bradstock, Richard De Abreu Lourenço, Chris Miles Frampton, Andrew G Spencer · 2014 · The Lancet Haematology
56. A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Gustav Jörgen Ullenhag, Eva D. Rossmann, Maria Liljefors · 2015 · PLoS ONE
57. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
    Éolia Brissot, Aline Clavert, Nicolas Blin, V Roland, Thierry Guillaume, Viviane Dubruille, Beatrice Mahé, Thomas Gastinne, Steven Le Gouill, Béatrice Gaugler et al. · 2015 · Leukemia
58. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
    Benedetto Bruno, Holger W. Auner, Gösta Gahrton, Laurent Garderet, Moreno Benedetto Festuccia, Marco Ladetto, Roberto Massimo Lemoli, Massimo Massaia, Curly Morris, Antonio Pierangelo Palumbo et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
59. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis
    Koji Kawamura, Takashi Ikeda, Shotaro Hagiwara, Takehiko Mori, Atsushi Shinagawa, Kaichi Nishiwaki, Kazuteru Ohashi, Shiro Kubonishi, Takahiro Fukuda, Toshiro Ito et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
60. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation
    Kelong Han, Laurent Claret, Alan B. Sandler, Asha Das, Jin Jin, René Bruno · 2016 · BMC Cancer
61. Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
    Ajay K. Nooka, Sagar Lonial · 2019 · The Cancer Journal
62. Selinexor for the treatment of patients with previously treated multiple myeloma
    Clifton Craig Mo, Sundar Jagannath, Ajai Chari, Ajay K. Nooka, Sagar Lonial, David Samuel DiCapua Siegel, Noa Biran, Cristina Gasparetto, Nizar Jacques Bahlis, Paul Gerard Guy Richardson · 2021 · Expert Review of Hematology
63. Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report
    Junxun Li, Jieyu Zhan, Fan Zhang, Zhuangjian Ye, Juan Ouyang · 2016 · Oncology Letters
64. Multiple Myeloma and Related Disorders
    S. Vincent Rajkumar, Angela A. Dispenzieri · 2020 · Elsevier eBooks
65. Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance
    Hani Hassoun, Mikhail Roshal, Joshua K. Sabari, James Nguyen, Qi Gao, Sean M. Devlin, Heather Jolie Landau, Nikoletta K. Lendvai, David J. Chung, Alexander M. Lesokhin et al. · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
66. The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma
    Almuth Maria Anni Merz, Maximilian Merz, Jens Hillengaß, Sarah A. Holstein, Philip L. McCarthy · 2019 · Expert Review of Anticancer Therapy
67. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!
    Dickran Gano Kazandjian, Alexander Dew, Elizabeth Hill · 2020 · Best Practice & Research Clinical Haematology
68. Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome
    Benjamin F. Chu, Arwa Shana’ah, Craig C. Hofmeister, Don Benson, Yvonne Adeduni Efebera · 2014 · European Journal of Case Reports in Internal Medicine
69. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma
    Omar Elghawy, S. Deshpande, Jonathan Sussman, Alfred L. Garfall, Adam D. Cohen, Shivani Kapur, Sandra P. Susanibar-Adaniya, Dan T. Vogl, Adam Justin Waxman, Edward Allen Stadtmauer · 2024 · Bone Marrow Transplantation
70. A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
    Enrica Antonia Martino, Giulio Caridà, Danilo Lofaro, A. Bruzzese, Caterina Labanca, Francesco Mendicino, E. Lucia, V. Olivito, Noemi Puccio, Antonino Neri et al. · 2025 · ESMO Open
71. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma
    Dipenkumar Modi, Jie Chi, Seongho Kim, Lois Jeanne Ayash, Asif Alavi, Andrew Daniel Kin, Voravit Ratanatharathorn, Joseph P. Uberti, Abhinav Deol · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
72. Cutaneous Multiple Myeloma
    Leela Krishna Vamsee Miriyala, Deepti Avasthi · 2021 · Cureus
73. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies
    Fatima Zahra Jelloul, Andres Ernesto Quesada, Richard Kenneth Yang, Shaoying Li, Wei Wang, Jie Xu, Guilin Tang, C. Cameron Yin, Hong Fang, Siba El Hussein et al. · 2023 · Modern Pathology
74. Therapy-related myelodysplastic syndromes and acute myeloid leukemia
    Sangeetha Venugopal, Amy Elizabeth Dezern · 2024 · Seminars in Hematology
75. The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
    Simon James Harrison, Hang Quach, Emma K. Link, Huaibao Feng, Joanne Dean, Michael C. Copeman, Helgi J. Van de Velde, Anthony P. Schwarer, Bartrum Baker, Andrew G Spencer et al. · 2015 · American Journal of Hematology
76. Initial Treatment of Transplant Candidates With Multiple Myeloma
    Philippe Moreau, Cyrille Touzeau · 2013 · Seminars in Oncology
77. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    Marc‐Andrea Baertsch, Jana Schlenzka, Elias Karl Mai, Maximilian Merz, Jens Hillengaß, Marc Steffen Raab, Dirk Hose, Patrick Wuchter, Anthony Dick Ho, Anna Sophia Jauch et al. · 2016 · BMC Cancer
78. Efficacy and safety of high‐dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma
    Li‐Wen Huang, Wendi Bacon, Constance Cirrincione, Bercedis L. Peterson, Gwynn Douglas Long, David Alan Rizzieri, Keith M. Sullivan, Kelly Corbet, Mitchell E. Horwitz, Nelson Jen An Chao et al. · 2017 · Hematological Oncology
79. Multiple Myeloma and Related Disorders
    S. Vincent Rajkumar, Angela A. Dispenzieri · 2014 · Elsevier eBooks
80. Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting
    Daniel Weiß, Robert Knight, Simon Yuji Zhou, Maria Palmisano, Nianhang Chen · 2015 · Clinical Drug Investigation
81. Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
    Jordan S. Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Elizabeth Rosko, Naresh Bumma, Abdullah Khan, Elvira R. Umyarova, Srinivas S. Devarakonda et al. · 2022 · Journal of Clinical Medicine
82. ‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?
    Yosef Joseph Rene Amel Riazat‐Kesh, John O Mascarenhas, Michal Bar‐Natan · 2023 · Blood Reviews
83. Multiple Myeloma and Second Malignancies
    Monika Martha Engelhardt, Ralph Wäsch, Ola Landgren, Martina Kleber · 2013 · Clinical Lymphoma Myeloma & Leukemia
84. Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
    Pascale Olivier, Anne-Charlotte Teisseyre, Jean‐Louis Montastruc · 2013 · Medical Oncology
85. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma
    T-F Wang, Mark Aaron Fiala, Amanda F. Cashen, Geoffrey L. Uy, Camille N. Abboud, T Fletcher, Ningying Wu, Peter Westervelt, John F. DiPersio, Keith E Stockerl-Goldstein et al. · 2014 · Bone Marrow Transplantation
86. Recommend maintenance therapy with lenalidomide in multiple myeloma
    Elisabet Esteve Manasanch · 2016 · Seminars in Oncology
87. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12)
    Kazutaka Sunami, Morio Matsumoto, Shin‐ichi Fuchida, Eijiro Omoto, Hiroyuki Takamatsu, Yoko Saeki Adachi, Ilsong Choi, Naohito Fujishima, Toru Kiguchi, Toshihiro Miyamoto et al. · 2019 · International Journal of Clinical Oncology
88. Limited treatment options in refractory multiple myeloma: promising therapeutic developments
    Albert Oriol, Laura Abril, Gladys Ibarra, Alicia Senín · 2019 · Expert Review of Anticancer Therapy
89. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
    Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Hellem Schjesvold, Roman Hájek, Philippe Moreau, Felipe de Arriba, María‐Victoria Mateos, Sharon West, Andrew G Spencer et al. · 2020 · Annals of Hematology
90. Old and new generation immunomodulatory drugs in multiple myeloma
    Daniele Derudas, Francesca Capraro, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
91. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada
    Donna Ellen Reece, Esther Masih‐Khan, Eshetu G. Atenafu, Victor Hugo Jimenez-Zepeda, Arleigh B. Robertson McCurdy, Kevin Song, Richard LeBlanc, Michaël Sébag, Darrell J. White, Hannah Marie Cherniawsky et al. · 2021 · European Journal Of Haematology
92. Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation
    Robert J. Soiffer, Yi‐Bin Chen · 2017 · Hematology
93. Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new?
    Irene M. Ghobrial · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
94. Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
    Roland R. Fenk, Aristoteles A. N. Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias Rummel, Nicolaus Martin Kröger, Amelie Boquoi, David Lopez, Celina Gerrlich, Julia Baier et al. · 2020 · Clinical Cancer Research
95. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
    Richard LeBlanc, S. Hollmann, Jason Tay · 2016 · PubMed
96. Update on the Initial Therapy of Multiple Myeloma
    Donna Ellen Reece · 2013 · American Society of Clinical Oncology Educational Book
97. Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion
    Kaci Shuman, Shannon Palmer, Brandi Anders, Dominic T. Moore, Jonathan R. Ptachcinski, Tatjana Grgic, Maurice D Alexander, Lauren Hill, Anthony Derek Sung, Paul M. Armistead et al. · 2022 · Transplantation and Cellular Therapy
98. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
    Ji Hyun Lee, Jimin Choi, Chang‐Ki Min, Sung‐Soo Park, Jae‐Cheol Jo, Yoo Jin Lee, Jin Seok Kim, Hyeon‐Seok Eom, Jongheon Jung, Joon Ho Moon et al. · 2024 · Haematologica
99. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
    Peter Michael Voorhees, Vera Jean Suman, Yvonne Adeduni Efebera, Noopur S Raje, Sascha Alexander Tuchman, Cesar Rodriguez Valdes, Jacob P. Laubach, Misty Bova‐Solem, Destin Carlisle, Saad Z. Usmani et al. · 2024 · Blood Advances
100. Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
     Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi · 2025 · Current Oncology Reports